Table 3.
A | B | C | D |
---|---|---|---|
Outcome | High CTRA expression |
Low CTRA expression |
p-value |
[% of cohort, 95% CI] |
[% of cohort, 95% CI] |
||
N=39 | N=39 | ||
Neutrophil recovery @ 100 days | 92 (83–98) | 85 (72–94) | 0.27 |
aGVHD @ 100 days | 49 (33–64) | 62 (46–76) | 0.25 |
cGVHD | 0.08 | ||
@ 1 year | 30 (16–45) | 35 (21–51) | 0.61 |
@ 3 years | 30 (16–45) | 47 (31–63) | 0.13 |
TRM | 0.61 | ||
@ 100 days | 33 (20–49) | 23 (12–38) | 0.33 |
@ 1 year | 44 (29–59) | 40 (25–56) | 0.74 |
@ 3 years | 44 (29–59) | 44 (28–60) | 0.98 |
Relapse | 0.04 | ||
@ 1 year | 18 (8–31) | 8 (2–19) | 0.2 |
@ 3 years | 31 (17–46) | 11 (3–23) | 0.04 |
LFS | 0.04 | ||
@ 1 year | 38 (24–54) | 52 (36–68) | 0.23 |
@ 3 years | 26 (13–41) | 45 (29–62) | 0.09 |
OS | 0.09 | ||
@ 1 year | 44 (29–59) | 54 (38–69) | 0.36 |
@ 3 years | 25 (12–42) | 47 (31–63) | 0.14 |
CTRA, conserved transcriptional response to adversity; GVHD, graft-versus-host disease (a=acute, c=chronic); LFS, leukemia-free survival; OS, overall survival; TRM, transplant-related mortality